| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2100711 | Best Practice & Research Clinical Haematology | 2012 | 7 Pages |
Abstract
Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Craig Moskowitz,